Diabetes Self-Management Blog

Innovative Insulin Pump Approved
On November 16, the US Food and Drug Administration (FDA) approved the t:slim insulin pump. The device is one of the first pumps to be cleared under the FDA’s new Infusion Pump Improvement Initiative, which establishes additional requirements for pump manufacturers to ensure safety and effectiveness.

The pump, which is approved for people with diabetes ages 12 and over who require insulin, will be the smallest insulin pump system available and up to 25% slimmer than other pumps, according to manufacturer Tandem Diabetes Care. The pump features a 300-unit cartridge and uses “micro-delivery technology” to facilitate accurate insulin dosing. Pump functions are controlled via a color touch screen; the associated t:connect data management software is compatible with both Macs and PCs. The batteries are rechargeable and, according to this article, will last roughly seven days without recharging.

Extensive user feedback was sought in designing the pump. According to Kim Blickenstaff, president and CEO of Tandem Diabetes Care, “In creating t:slim, we spoke with more than 4,000 healthcare professionals and people with diabetes, and the clear message we heard was, ‘make it cool and make it uncomplicated to use. Give us access to the most advanced features without extra effort.’ The t:slim’s touch screen interface has been proven in extensive user studies to be easy to learn and to use by new and experienced pump users alike.”

The t:slim is expected to hit the US market sometime in early 2012.

For more information about the t:slim insulin pump, see the Tandem Diabetes Care Web site or check out the related blog entry on Diabetes Mine.

Avandia Restricted to Mail-Order
In other news, the diabetes drug Avandia (rosiglitazone) and combination medicines containing this drug are now available solely through certified mail-order pharmacies and can no longer be obtained in retail pharmacies.

In 2010, the FDA required the manufacturer to create a restricted-access program for the drug after a large meta-analysis (in which statistics from several studies are combined and examined) indicated that Avandia was associated with a substantially increased risk of heart attack. As of November 18, only those enrolled in the Avandia-Rosiglitazone Medicines Access Program can receive Avandia, Avadamet, or Avandaryl. The program restricts use of these medicines to people who have not been able to control their diabetes with other medicines and who have decided, in consultation with their health-care provider, not to take Actos (pioglitazone), the other drug in the thiazolidinedione class.

For more information on the access program, click here.

POST A COMMENT       
  

Comments
  1. There are no comments at this time.


Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Tools & Technology
Information at Our Fingertips (09/04/14)
Support Medicare Coverage of CGMs (09/02/14)
Children With Diabetes "Focus on Technology" Conference (07/28/14)
Bionic Pancreas Trials Currently Recruiting (07/03/14)

Oral Medicines
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
New SGLT Drugs Coming (07/23/14)
Metformin More Effective in African-Americans (07/10/14)

Diabetes News
Antibiotics Linked to Lows in People Taking Certain Diabetes Drugs (09/11/14)
Low-Carb Diet Benefits Type 2 Diabetes, Heart Health, Studies Show (09/03/14)
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)

Diane Fennell
Antibiotics Linked to Lows in People Taking Certain Diabetes Drugs (09/11/14)
Low-Carb Diet Benefits Type 2 Diabetes, Heart Health, Studies Show (09/03/14)
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.


Blood Glucose Self-Monitoring — Part 2: Technique

What Stress Is Doing to Your Brain

Diabetic Cooking: The Summer Issue

Complete table of contents
Get a FREE ISSUE
Subscription questions